You are here:--Glenn S Tillotson

Glenn S Tillotson

Glenn Tillotson is a Partner at GST Micro, and a consultant to the pharmaceutical and diagnostic industries, providing advice on a range of topics covering preparatory and post-approval activities.

Glenn has over 30 years’ pharmaceutical experience in clinical research, commercialization and, scientific communications including publications planning, strategic drug development, life cycle management and global launch programmes.

Before becoming a consultant, Glenn was Senior Vice President (SVP) of Medical Affairs at Cempra, in charge of publication planning, medical information, opinion leader development, health economics and outcomes research, and the management of external investigator studies. Before that he was SVP of Medical Affairs at Optimer Pharmaceuticals, and at ViroPharma where he led the medical education programmes for Vancocin, maribavir, non-toxigenic Clostridium difficile and the successful US launch of Cinryze. He has been Executive Director of Scientific Affairs at Replidyne, and VP of Scientific and Medical Relations at Oscient Pharmaceuticals.

After training in medical microbiology and infectious diseases in the UK, Glenn spent 13 years at Bayer AG in the UK, US and Germany, where he was instrumental in the development of ciprofloxacin and moxifloxacin as well as other drugs in the company’s portfolio.

Glenn has published over 170 articles, been a member of several editorial advisory boards including Lancet Infectious Diseases and, has been a member of scientific steering committees for a range of international congresses.

He holds a MSc in medicine from the University of Manchester, a PhD in medical microbiology from Richmond University, London, and fellowships of the Infectious Disease Society of America and American College of Chest Physicians.

2018-03-16T10:39:53+00:00